Premium
The outlook for peptide drugs and the intricate relationship between the Active Pharmaceutical Ingredients manufacturer and their sponsors
Author(s) -
de Chastonay Jose
Publication year - 2005
Publication title -
journal of peptide science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 66
eISSN - 1099-1387
pISSN - 1075-2617
DOI - 10.1002/psc.718
Subject(s) - commercialization , active ingredient , business , pharmaceutical industry , drug , drug industry , pharmacology , chemistry , medicine , biochemical engineering , marketing , engineering
As research laboratories discover an ever‐increasing number of peptides of pharmacological interest, there is an increased need for Good Manufacturing Practices (GMP) services, as these drugs candidates undergo clinical trials. It is therefore essential to understand the importance of the relationship with the Active Pharmaceutical Ingredients (API) manufacturer and its implications in the development and commercialization of the future peptide drug. Copyright © 2005 European Peptide Society and John Wiley & Sons, Ltd.